PTC Therapeutics' Gene Therapy Plans Hit By Pandemic
Ela-Vec Sees EU And US Regulatory Delays
PTC Therapeutics is one of many companies in the life sciences sector whose regulatory targets have been adversely affected by the coronavirus pandemic.
You may also be interested in...
The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.
Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.
The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.